GE Healthcare Announces Phase I Results With Amyloid Imaging Agent GE-067

Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

GE Healthcare, a unit of the General Electric Company (NYSE:GE), announced positive results from a Phase I clinical trial of GE-067, a [18F]-labeled PET diagnostic imaging agent being developed by the company to assist in the detection of brain beta-amyloid.

More: continued here









Leave a Reply